News

Neurocrine Biosciences is close to securing a more than $2.5bn acquisition of Soleno Therapeutics, the developer of a treatment for a rare genetic form of obesity. The talks, described as advanced, highlight how midsized drugmakers are increasingly pursuing strategic...

Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, in a move that significantly expands its presence in immunology and rare diseases. The Biogen to Acquire Apellis deal stands among the company’s largest transactions to date,...

The US pharma tariffs policy has been formalised through an executive order signed by Donald Trump, introducing tariffs of up to 100% on imported branded medicines. The measure targets pharmaceutical companies that have not entered into drug pricing agreements...

Advances in biomaterials and localized drug delivery systems are transforming implant surgery across both medical and dental disciplines. Traditionally, implant success relied primarily on mechanical stability and surgical technique. Today, innovations in bioactive materials, surface engineering, and controlled drug delivery...

Britain has finalised a UK-US pharma trade deal, securing tariff-free access for UK-made medicines to the United States while committing to higher domestic spending and pricing adjustments for new drugs. The agreement, part of a broader bilateral trade framework...

Eli Lilly & Co. is set to acquire Centessa Pharmaceuticals Plc in a transaction worth up to $7.8 billion, underscoring its push to broaden its drug development pipeline. The Centessa Pharmaceuticals deal highlights the company’s effort to expand into therapeutic...

New findings from healthcare consulting and technology company D2 Solutions indicate that medication access delays are influencing whether patients initiate prescribed therapies, with confusion and administrative hurdles emerging as key barriers. Based on a survey of 1,000 U.S. adults...